scholarly journals NF1 May Serve As A Novel Genetic Biomarker Of Response To Treatment And Prognosis In Glioblastoma (GBM)

2020 ◽  
Vol 108 (3) ◽  
pp. e711
Author(s):  
B. Huang ◽  
J. Yang ◽  
K. Wang ◽  
W. Chen ◽  
H. Ni ◽  
...  
Keyword(s):  
Response To Treatment ◽  
Genetic Biomarker

NF1 may serve as a novel genetic biomarker of response to treatment and prognosis in glioblastoma (GBM).

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e14539-e14539
Author(s):  
Bin Huang ◽  
Ju Yang ◽  
Kongcheng Wang ◽  
Weitao Chen ◽  
Hongbin Ni ◽  
...  
Keyword(s):  
Biomarker Discovery ◽  
Early Recurrence ◽  
Response To Treatment ◽  
Normal Brain ◽  
Tumor Associated Macrophages ◽  
Genome Wide ◽  
A Genome ◽  
Intrinsic Capacity ◽  
The Relationship ◽  
Genetic Biomarker

e14539 Background: The intrinsic capacity of glioblastoma (GBM) tumor cells to infiltrate normal brain predictably results in high rates of early recurrence. Little has changed over the last decade in the treatment available for GBM with survival remaining poor and a novel genetic biomarker is necessary found to predict response to treatment and prognosis in GBM. Methods: Biomarker discovery was performed by a genome-wide screen using DNA extracted from tissue and blood samples of GBM patients. The biomarker was then evaluated for its predictability in OS of GBM patients compared with the Chinese Glioma Genome Atlas (CGGA) and revealed the relationship with tumor-associated macrophages (TAMs). Results: Median OS for NF1-deleted/mutated GBM patients (n = 11) treated with surgery and Chemoradiotherapy was 9.1 mon vs 17.2 mon for NF1 wildtype ones(n = 47), HR (95% CI) 1.83 (0.8753,3.817), p = 0.1. In addition, NF1-deleted/mutated GBMs showed reduced tumor purity and more infiltration of tumor-associated macrophages through pathological stainings. Conclusions: These data suggest that NF1-deleted/mutated GBM patients have a poor prognosis and NF1 may play a role in organizing the tumor microenvironment. NF1 in GBM will be further evaluated in a planned randomized ph 2b study in newly diagnosed GBM patients.

Effects of the pseudomonad phytotoxin coronatine on tomato leaf structure and ultrastructure

1995 ◽  
Vol 53 ◽  
pp. 862-863
Author(s):  
D.A. Palmer ◽  
C.L. Bender
Keyword(s):  
Pseudomonas Syringae ◽  
Membrane Integrity ◽  
Leaf Tissue ◽  
Cell Number ◽  
Cell Ultrastructure ◽  
Response To Treatment ◽  
Prominent Symptom ◽  
Chlorophylls A And B ◽  
Cell Dimensions ◽  
Structure And Ultrastructure

Coronatine is a non-host-specific phytotoxin produced by several members of the Pseudomonas syringae group of pathovars. The toxin acts as a virulence factor in P. syringae pv. tomato, allowing the organism to multiply to a higher population density and develop larger lesions than mutant strains unable to produce the toxin. The most prominent symptom observed in leaf tissue treated with coronatine is an intense spreading chlorosis; this has been attributed to a loss of chlorophylls a and b in tobacco. Coronatine's effects on membrane integrity and cell ultrastructure have not been previously investigated. The present study describes changes in tomato leaves in response to treatment with purified coronatine, infection by a coronatine-producing strain of P. syringae pv. tomato, and infection by a cor" mutant.In contrast to H2O-treated tissue, coronatine-treated tissue showed a diffuse chlorosis extending approximately 5 mm from the inoculation site. Leaf thickness, cell number, and cell dimensions were similar for both healthy and coronatine-treated, chlorotic tissue; however, the epidermal cell walls were consistently thicker in coronatine-treated leaves (Figs, la and lb).

Gender-related differences in pathogenesis and response to treatment of bone disorders of celiac disease (CD) patients

2001 ◽  
Vol 120 (5) ◽  
pp. A392-A392
Author(s):  
J FERRETI ◽  
R MAZURE ◽  
P TANOUE ◽  
A MARINO ◽  
G COINTRY ◽  
...  
Keyword(s):  
Celiac Disease ◽  
Response To Treatment ◽  
Bone Disorders

Response to Treatment of Alcoholism; a Follow-Up Study

1968 ◽  
Vol 29 (2) ◽  
pp. 364-381 ◽  
Author(s):  
Alex D. Pokorny ◽  
Byron A. Miller ◽  
Sidney E. Cleveland
Keyword(s):  
Response To Treatment ◽  
Follow Up Study

TREATMENT OF NON-TOXIC GOITRE WITH THYROID PREPARATIONS

1960 ◽  
Vol XXXIII (IV) ◽  
pp. 584-592 ◽  
Author(s):  
B.-A. Lamberg ◽  
C. A. Hernberg ◽  
Riitta Hakkila
Keyword(s):  
Radioactive Iodine ◽  
Response To Treatment ◽  
Iodine Uptake ◽  
Nodular Goitre ◽  
Radioactive Iodine Uptake ◽  
Observation Period

ABSTRACT Treatment with a thyroid preparation was used in 75 cases of non-toxic goitre. In 63 cases there was nodular goitre in 12 diffuse goitre. The observation period varied from 3 to 42 months. The size of the goitre decreased in 50 cases (68 per cent) of which 40 had a nodular goitre and 10 a diffuse goitre. In the 63 cases with a nodular goitre the size of the nodules decreased in 39 cases and the nodules disappeared completely in 2 cases (65 per cent). In 5 cases (7 per cent) there was no change in the size of the thyroid or the nodules. Temporary factitious hyperthyroidism appeared in 7 cases but subsided rapidly after adjustment of the dose. In one case an endogenous hyperthyroidism evidently developed, probably owing to initial latent hyperthyroidism. Treatment of non-toxic goitre with thyroid preparations or hormones is recommended 1) in diffuse goitre, 2) in nodular goitre as a trial and 3) after thyroidectomy for compressive goitre. The value of radioactive iodine uptake or excretion tests for the assessment of the response to treatment and the adjustment of the dose is emphasized.

Sign in / Sign up

Export Citation Format

Share Document